Ablation Frontiers is a technology company.
Ablation Frontiers is a technology company.
Ablation Frontiers has raised $22.0M across 1 funding round.
Ablation Frontiers has raised $22.0M in total across 1 funding round.
Ablation Frontiers was a medical device company that developed catheter-based radiofrequency (RF) ablation technologies for treating atrial fibrillation (AF) and other cardiac arrhythmias.[1][2][3] It served cardiologists and electrophysiologists performing AF ablation procedures, addressing the need for simpler, safer, and more predictable therapies compared to existing methods by offering anatomically designed catheters and an RF energy system.[1] The company, based in Carlsbad, California, achieved early European market entry with CE Mark approval in 2006 and was pursuing U.S. FDA approval via clinical trials, but was acquired by Medtronic in 2009 for an initial $225 million plus milestones, integrating its tech into Medtronic's AF Solutions franchise.[1][2][5]
Founded in 2004, Ablation Frontiers emerged as a VC-backed startup focused on advancing cardiac ablation for AF patients.[3][5] Little public detail exists on specific founders, but the company quickly innovated anatomically tailored catheters and RF systems, earning CE Mark in 2006 for European sales and launching U.S. FDA IDE trials for chronic AF.[1] Pivotal traction came through these approvals and clinical progress, culminating in Medtronic's acquisition announcement in January 2009 (closing by April), following Medtronic's prior CryoCath buy to broaden its ablation portfolio.[1][2]
Ablation Frontiers rode the early-2000s surge in catheter ablation for AF, a growing alternative to drugs as AF prevalence rose with aging populations and better diagnostics.[1] Timing aligned with medtech consolidation, as giants like Medtronic built comprehensive AF franchises amid demand for less invasive cardiac rhythm management.[1][2] Market forces favoring it included clinician preferences for efficient tools and regulatory progress enabling scale; post-acquisition, its tech influenced Medtronic's ecosystem, enhancing physician options in RF alongside cryoablation.[1]
Post-2009 acquisition, Ablation Frontiers' standalone story ended, with its RF tech absorbed into Medtronic's enduring ablation portfolio, still referenced in their surgical energy offerings.[4] Future shape comes via Medtronic's evolution in AF treatments amid trends like AI-guided ablations and expanded indications. Its influence persists indirectly, bolstering Medtronic's market leadership in cardiac devices and underscoring how specialized medtech startups fuel giants' dominance in life-saving therapies.[1][4]
Ablation Frontiers has raised $22.0M in total across 1 funding round.
Ablation Frontiers has raised $22.0M across 1 funding round. Most recently, it raised $22.0M Series C in July 2007.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2007 | $22.0M Series C |